AbsciABSI
ABSI logo
Fair Value
US$4.54
Share price09 Jan
US$10.6133.6% overvalued intrinsic discount
Loading
1Y298.50%
7D-8.15%

Early-Stage Prolactin Antibody Risks Will Eventually Support Long-Term Hair Loss And Endometriosis Potential

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
09 Jan 26
Views
26
Not Invested

Fair Value vs Share Price

US$4.54
vs US$10.6133.6% overvalued intrinsic discount
PastFuture-121m6m2019202120232025202620272029Revenue US$4.5mEarnings US$736.4k
17.2%
Revenue growth
16.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Absci

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with slight risk.

Market capUS$1.8b
PB10.4x
Estimated Growth49.7%
Dividend YieldN/A
Full analysis

CEO & management

Sean McClain
CEO
3.3yrs
CEO Tenure

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.